charlieaja / iStockphoto.com
With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports.
The UK’s departure from the EU has been the topic of much sparring and speculation since the controversial vote in June 2016, but one important implication of Brexit has been little discussed in the mainstream news: medicines regulation.
Brexit’s impact on the UK life sciences industry is likely to be significant, and the ultimate extent to which researchers, manufacturers and the general public are affected will depend on the terms governing the EU-UK relationship post-Brexit, says Roberto Valenti, partner in DLA Piper’s Milan office.
The European Medicines Agency (EMA) is the EU regulator for human and veterinary medicines, although the regulatory bodies of national member states have some flexibility in how they implement the relevant framework.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
Medicines regulation, Brexit, European Medicines Agency, Directive 2001/83/EC, Regulation (EC) no. 726/2004